Newly Diagnosed mHSPC: First-Line Treatment Options

Evan Y. Yu, MD, discusses how systemic therapy options for newly diagnosed metastatic hormone-sensitive prostate cancer include androgen deprivation therapy (ADT) combined with chemotherapy or androgen receptor pathway inhibitors (ARPIs) such as abiraterone or enzalutamide, with the choice of frontline treatment depending on factors such as disease burden and patient characteristics, while also considering the structural and physical differences between these ARPIs, which may influence their efficacy and adverse effect profiles.

EP: 1.Introduction & Case 1 Presentation: mHSPC

EP: 2.Newly diagnosed Diagnosed mHSPC: Goals of Therapy

Now Viewing

EP: 3.Newly Diagnosed mHSPC: First-Line Treatment Options

Video content above is prompted by the following:

1. What systemic therapy options would you discuss with this patient?
   1. Which do you consider for frontline treatment?
   2. Thinking about the individual ARPI used in this setting, what are their similarities and differences in terms of structural formula and physical properties?
      

Recent Videos